3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
54
Recurrence
6
Neoplasms, Plasma Cell
3
Plasmacytoma
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Various Advanced Cancer
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Personal Satisfaction
1
Patient Satisfaction
1
Patient Preference
1
Pancreatic Neoplasms
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Hodgkin Disease
1
Carcinoma, Renal Cell
1
Amyloidosis
1
Acute Kidney Injury
1
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
daratumumab
×
Clear all
NCT05284591
2024-10-01
MYLENE
iOMEDICO AG
Completed
96 enrolled